Skip to main content
. 2021 Nov 16;42(1):161–172. doi: 10.1111/liv.15090

FIGURE 1.

FIGURE 1

Attack frequency and hemin use with long‐term givosiran treatment. A, Median AAR. †Descriptive analysis. ‡Placebo crossover patients receiving givosiran 2.5 mg/kg (n = 29) or 1.25 mg/kg (n = 17). B, Proportion of patients with zero attacks by 3‐month intervals. Baseline represents 6 months prior to randomization. §One patient did not meet an inclusion criterion and was enrolled in the study (did not have the requisite number of attacks in the 6 months prior to randomization). Composite attacks include porphyria attacks requiring hospitalization, urgent healthcare visit, or intravenous hemin administration at home. 1 month = 28 days. C, Median annualized days of hemin use. D, Proportion of patients with zero days of hemin use. E, Proportion of patients with zero days of hemin use by 3‐month intervals. AAR, annualized attack rate; DB, double‐blind; Givo, givosiran; OLE, open‐label extension; PBO, placebo